BioSpace News Archive

Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, announced a partnership with Illumina, Inc., aimed at assessing the real-world uptake and actionability of comprehensive genomic profiling in the community oncology health system setting.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that management will participate in two upcoming investor conferences and a medical meeting.

Sorrento Therapeutics, Inc., announced that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming panel at the Longwood Healthcare Leaders Winter Conference.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present at the H.C. Wainwright BIOCONNECT Virtual Conference.

Boston Scientific Corporation (NYSE: BSX) will participate in the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, has been granted a U.S. patent (11,207,350 B2) for a novel natural killer (NK) cell therapy composition and method for treating cancer that combines the company’s genetically modified NK-92 cells with CD16 receptors to enhance binding and activity of monoclonal antibodies.

Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference.

Spectrum Pharmaceuticals today announced a $20 million equity investment by Hanmi Pharmaceutical along with revisions to the licensing agreements for ROLONTIS ® (eflapegrastim) and poziotinib.

Acorda Therapeutics, Inc. announced that Ron Cohen, MD, President and CEO, will present at the H.C. Wainwright BIOCONNECT Virtual Conference, taking place from January 10 – 13, 2022.

Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance.